Warning out on 2 recalled drugs | Inquirer News

Warning out on 2 recalled drugs

By: - Reporter / @santostinaINQ
/ 12:35 AM April 06, 2014

MANILA, Philippines – The Food and Drug Administration (FDA)  issued warnings to consumers and medical practitioners on Saturday after two pharmaceutical companies recalled batches of medicines, one for heart disease and the other for breast cancer.

In an advisory, the FDA said Abbott Laboratories-Philippines had initiated a voluntary recall of Triflusal 300 mg capsule (Grendis) up to the retail level. Covered by the recall are capsules under batch number H003, with registration number DR-XY30166.

Manufactured by J. Uriach & CIA, S.A.,  in Barcelona, Spain, in March 2013, the products have an expiry date of March 2016, it said.

Article continues after this advertisement

Triflusal is an antiplatelet drug also used to treat angina, nonhemorrhagic stroke or transient ischemic attack and reduction of vein graft occlusion after coronary bypass surgery.

FEATURED STORIES

The agency said Abbott ordered a recall after receiving a complaint from the Malaysian market that another batch of the product (H005) distributed in that country had a “bad smell.”

An investigation at the manufacturing site found that the smell was due to an increase in one of the impurities, which was then traced to a damage in the refrigeration system, the FDA said.

Article continues after this advertisement

The health agency said pharmacies in the country should stop selling the product batch, while consumers who had already bought it should return it to where it was purchased. Consumers are also urged to report any adverse reaction caused by the product at [email protected].

Article continues after this advertisement

In another advisory, the FDA said Fresenius Kabi Philippines Inc. had also started the recall of Paclitaxel 30 mg/1.5 ml Solution for Nanoparticle Injection (Nanoxel).

Article continues after this advertisement

Covered by the recall are medicines under batch numbers 873TF00103 (nanoxel injection) and 873RX001 (accompanying concentrate of excipients), which were manufactured in January 2013 and with an expiry date of December 2014.

The product is used in the treatment of breast cancer, the agency said. It is packaged in a box containing one vial of paclitaxel solution and one vial of the concentrate.

Article continues after this advertisement

The recall was prompted by observations that the supposedly clear or colorless concentrate of excipients in the batch had turned yellow even before the end of its shelf life.

Consumers with questions regarding the recall may contact Fresenius Kabi Philippines Inc. safety officer Cristina Aguilar-Cu at 8896492 local 111, or e-mail [email protected]

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Drugs, FDA, Medicines, Paclitaxel, Philippines, Triflusal

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.